1. Home
  2. DRIO vs ACRV Comparison

DRIO vs ACRV Comparison

Compare DRIO & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DarioHealth Corp.

DRIO

DarioHealth Corp.

HOLD

Current Price

$11.89

Market Cap

82.2M

Sector

Health Care

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.53

Market Cap

82.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRIO
ACRV
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.2M
82.7M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
DRIO
ACRV
Price
$11.89
$2.53
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$50.00
$14.67
AVG Volume (30 Days)
31.4K
531.6K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,732,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$20.02
$805.20
P/E Ratio
N/A
N/A
Revenue Growth
7.29
N/A
52 Week Low
$5.94
$1.05
52 Week High
$31.00
$8.00

Technical Indicators

Market Signals
Indicator
DRIO
ACRV
Relative Strength Index (RSI) 44.95 59.17
Support Level $11.77 $2.44
Resistance Level $13.30 $2.73
Average True Range (ATR) 0.90 0.17
MACD 0.03 0.01
Stochastic Oscillator 20.00 64.91

Price Performance

Historical Comparison
DRIO
ACRV

About DRIO DarioHealth Corp.

DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: